Clinical Trials
102 trialsA Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ADAPT-BLADDER
Hoosier Cancer Research Network
ENHANCE
Hoosier Cancer Research Network
GAIN-BCG
Alliance for Clinical Trials in Oncology
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
H. Lee Moffitt Cancer Center and Research Institute
VG-INFUSE Tria
Fudan University
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
PRO-GAG
BLAD-HYA Group
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
CRUCIAL-R
S. Andrea Hospital
Hydeal Cyst
Istituto Oncologico Veneto IRCCS
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
Aarhus University Hospital
SPICE
University of Aarhus
PERTINENCE
Institut Cancerologie de l'Ouest
CUT-less
University of Roma La Sapienza
BicaBCa
CHU de Quebec-Universite Laval
TRAIN
The Christie NHS Foundation Trust
PERSEVERANCE
Institut Cancerologie de l'Ouest
NMIBC
Xijing Hospital
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HERO
Fudan University
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
COBRA-NMIBC
Aarhus University Hospital
GEM-IR-NMIBC
Shanghai University of Traditional Chinese Medicine
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lahey Clinic
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Ractigen Therapeutics.
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
BCG-TIME
Queen's University
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
The First Affiliated Hospital with Nanjing Medical University
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
Memorial Sloan Kettering Cancer Center
COBRA
Medical University of Vienna
Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial
National Taiwan University Hospital
eRapa
The University of Texas Health Science Center at San Antonio
HIGCrecur
Changhai Hospital
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
Tongji Hospital
Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer
Helwan University
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
Ankara University
PRIMER
University of Virginia
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
University Teaching Hospital Hall in Tirol
DURANCE
University College, London
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
Mansoura University
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Fujian Medical University Union Hospital